Coloplast A/S Series B,

Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
  • TickerCOLO B
  • ISINDK0060448595
  • ExchangeNasdaq Nordic Copenhagen
  • SectorHealth Care Equipment & Services
  • CountryDenmark

Analysts

Debbie Wang

Morningstar | COLO B Updated Forecasts and Estimates from 05 Feb 2019

Narrow-moat Coloplast posted another strong quarter that featured organic top-line growth that outpaced the market and met our expectations on the bottom line. After making slight adjustments to our model, we’re standing behind our fair value estimate of DKK 610 per share. Strong 8% organic growth from both the ostomy and incontinence care segments were par for the course. However, we were more impressed with 10% organic growth from the wound care business fueled by adoption of the Biatain Silicone foam portfolio, following a flat year in fiscal 2017-18. While the robust first-quarter performa...

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Debbie Wang

Morningstar | Coloplast Posts Strong Fiscal First Quarter, and Our Fair Value Estimate Is Unchanged

Narrow-moat Coloplast posted another strong quarter that featured organic top-line growth that outpaced the market and met our expectations on the bottom line. After making slight adjustments to our model, we’re standing behind our fair value estimate of DKK 610 per share. Strong 8% organic growth from both the ostomy and incontinence care segments were par for the course. However, we were more impressed with 10% organic growth from the wound care business fueled by adoption of the Biatain Silicone foam portfolio, following a flat year in fiscal 2017-18. While the robust first-quarter performa...

A director bought 38,300 shares at 521.960DKK and

A director at Coloplast As bought 38,300 shares at 521.960DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Christer Magnergård ...
  • Martin Arnell
  • Mattias Holmberg
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Rune Majlund Dahl

Northern Lights

Christer Magnergård ...
  • Eivind Sars Veddeng
  • Jesper Ingildsen
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Antti Kansanen
  • Håkon Astrup
  • Helge André Martinsen
  • Jon Masdal
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Mattias Holmberg
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Paul Harper
  • Rune Majlund Dahl

Northern Lights

Alexander Aukner ...
  • Antti Kansanen
  • Frank Maaø
  • Mattias Montgomery
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Mattias Holmberg ...
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Expert Corporate Governance Service (ECGS)

Coloplast - 2018, December 5th

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. On November 1, 2018, the Company announced that Mr. L.S. Rasmussen will resign from his position as CEO to become the new Chairman of the board of directors as of this AGM. Mr. Rasmussen will be succeeded by Executive Vice President - Mr. Kristian Villumsen - as of the same date.   Under ITEM 5.1, it is proposed to re-appoint Mr. N.P. Louis Hansen as Vice Chairman of the board of directors. Although ECGS has no (major) concerns over the re-appointment...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 07/12/2017

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.Under ITEMS 5a-5g, the (re-)election of the board of directors is proposed.Under ITEM 5a, it is proposed to re-appoint Mr. Michael Pram Rasmussen as Chairman of the board of directors. Although Mr. Pram Rasmussen is deemed independent, ECGS has various other concerns over his re-appointment. Therefore, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.Under ITEM...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch